SETUP

HUM is breaking out on strong volume with a fresh daily MACD bullish crossover at $387.97, up 1.91% today. Price is recovering from a brutal 52-week low of $163.11 and is now clawing back toward the $428.88 high. The 63-day relative strength is exceptional at +26.75% over SPY, signaling institutional accumulation in a beaten-down managed care name. The bar closed at the high of the session, showing no intraday distribution. This looks like a mean-reversion momentum trade with legs, not just a dead-cat bounce.

CATALYSTS

The April 2025 earnings beat was significant at +15% above estimates, the largest beat in five quarters, suggesting medical cost trends may finally be stabilizing. Medicare Advantage headwinds that crushed the stock from 2024 highs appear to be priced in. News flow around Star Ratings rebound is a genuine catalyst — higher Star Ratings directly unlock MA plan payment bonuses, which could materially lift forward earnings. The sector broadly is benefiting from easing MLR fears. New CMO appointment signals management is investing in clinical strategy long-term.

RISKS

The P/E at 36.6x on $10.57 EPS is elevated for a managed care name under ongoing MA margin pressure. The 93% dividend payout ratio is a red flag — this is unsustainable if earnings slip and could signal the dividend is at risk. Insider activity on May 1 shows multiple officers receiving shares, but these appear to be compensation grants, not open-market buys — limited conviction signal. Signal Quality Score of 50/100 warns this entry may be extended. Any deterioration in CMS reimbursement rates, MLR guidance, or renewed MA enrollment softness could reverse this move quickly. Stop at $364.97 represents a 5.9% drawdown — manageable but requires discipline.

CONVICTION: Medium

Strong earnings momentum and sector rotation support the move, but the stretched valuation, questionable dividend sustainability, and average signal quality score limit conviction to a starter position.